Quality of life after laparoscopic and open retroperitoneal lymph node dissection in clinical Stage I nonseminomatous germ cell tumor: A comparison study

Poulakis, Vassilis; Skriapas, Konstantinos; Vries, Rachelle de; Dillenburg, Wolfgang; Ferakis, Nikolaos; Witzsch, U.; Becht, E.

doi:10.1016/j.urology.2006.01.023

Cited by 63 publications

(37 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8,9 L-RPLND has demonstrated improved convalescence and quality of life compared with open RPLND. 10,11 In similar fashion, a report on robot-assisted L-RPLND will continue to increase the minimally invasive nature of the procedure. 12 In a comprehensive review of the current status of L-RPLND, 13 the strengths and limitations of the approach were portrayed and indicated that longer oncologic follow-up is necessary for this promising approach.…”

Section: Introductionmentioning

confidence: 96%

Laparoscopic Retroperitoneal Lymph Node Dissection for Low-Stage Testicular Cancer

Skolarus

Bhayani

Chiang

et al. 2008

Journal of Endourology

View full text Add to dashboard Cite

Skolarus, T. A.; Bhayani, S. B.; Chang, H. C.; Brandes, S. B.; Kibel, A. S.; Landman, J.; and Figenshau, R. S., ,"Laparoscopic retroperitoneal lymph node dissection for low-stage testicular cancer." Journal of Endourology.22,7. 1485Endourology.22,7. -1490Endourology.22,7. . (2008 Results: A total of 26 L-RPLND procedures were completed, 3 for paratesticular rhabdomyosarcoma. Mean operative time was 250 minutes (range 176-369 min); estimated blood loss was 145 mL (range 50-500 mL); lymph node count was 23.8 (range 8-48); and hospital stay was 1.5 days (range 1-3 d). Four patients underwent postchemotherapy L-RPLND for residual nodes (1.1-2.9 cm). There were no conversions to an open procedure, blood transfusions, or operative complications. Chemotherapy was instituted in five of six patients with pathologic stage II disease. Mean follow-up was 23.7 months without retroperitoneal disease recurrence. Conclusion: L-RPLND as a diagnostic and therapeutic tool provides the benefits of a minimally invasive approach to MMGCT. It is the procedure of choice at our institution for low-stage MMGCT and paratesticular rhabdomyosarcoma.

show abstract

Section: Introductionmentioning

confidence: 96%

Laparoscopic Retroperitoneal Lymph Node Dissection for Low-Stage Testicular Cancer

Skolarus

Bhayani

Chiang

et al. 2008

Journal of Endourology

View full text Add to dashboard Cite

show abstract

“…Under ideal conditions, RPLND provides excellent results (i.e., 90% survival with low long-term toxicity). 21 However, patients might be exposed to surgery-associated side effects such as retrograde ejaculation. The relapse rate after RPLND is between 5.8% and 21% in the literature.…”

Section: Discussionmentioning

confidence: 99%

Clinical outcomes in patients with stage I non-seminomatous germ cell cancer

Lv¹,

Wu²,

Dong³

et al. 2013

Asian J Androl

View full text Add to dashboard Cite

This study assesses the long-term outcomes in Han Chinese patients with clinical stage I non-seminomatous germ cell testicular cancer (CSI NSGCT) treated with surveillance, retroperitoneal lymph node dissection (RPLND) and adjuvant chemotherapy. We retrospectively evaluated 89 patients with a mean age of 26.5 years. After orchiectomy, 37 patients were treated with surveillance, 34 underwent RPLND and 18 were managed with chemotherapy. The overall survival rate, the recurrence-free survival rate and the risk factors were evaluated. The median follow-up length was 92 months (range: 6-149 months). Thirteen of the 89 patients (14.6%) had relapses, and one died by the evaluation date. The overall survival rate was 98.9%. The cumulative 4-year recurrence-free rates were 80.2%, 92.0% and 100% for the surveillance, RPLND and chemotherapy groups, respectively. The disease-free period tended to be briefer in patients with a history of cryptorchidism and those with stage Is. Therefore, surveillance, RPLND and adjuvant chemotherapy might be reliable strategies in compliant patients with CSI NSGCT. Surveillance should be recommended for patients with the lowest recurrence rate, especially those without lymphovascular invasion. This study might aid the establishment of a standard therapy for CSI NSGCT in China.

show abstract

“…No obstante, complicaciones postoperatorias menores iniciales y tardías fueron significantemente altas en la LR. Los pacientes de LRL estuvieron bastante menos tiempo ingresados, tuvieron mejores escalas de calidad de vida y mayor rapidez en el retorno a la vida diaria 15 . Abdel-Azi et al compararon su experiencia basada en 28 pacientes que fueron sometidos a LR (6 pacientes) o LRL (22 pacientes) para TCGNS en estadio clínico I.…”

Section: Discussionunclassified

Linfadenectomía retroperitoneal laparoscópica primaria para el tumor testicular de células germinales no seminomatoso en estadio clínico I

et al. 2011

View full text Add to dashboard Cite

Recibido el 4 de julio de 2010; aceptado el 19 de agosto de 2010 Accesible en línea el 6 de enero de 2011 PALABRAS CLAVECáncer de testículo; Neoplasia no seminomatosa de células germinales; Laparoscopia; Disección retroperitoneal de ganglios linfáticos ResumenIntroducción: el propósito de este informe es evaluar retrospectivamente el seguimiento de cáncer y la mortalidad en linfadenectomía retroperitoneal laparoscópica (LRL) primaria en pacientes con tumor de células germinales no seminomatoso (TCGNS) es estadio clínico I. Materiales y métodos: ciento sesenta y cuatro pacientes con TCGNS en estadio clínico I se sometieron a LRL diagnóstica primaria entre 1993 y 2006. Los pacientes fueron operados unilateralmente limitando la disección a áreas. Se generaron curvas Kaplan Meier estimando el período de recurrencia. Resultados: de los 164 pacientes 82 (48%) tenían componentes embrionarios y 35 (20%) invasión linfovascular en la muestra de orquiectomía. La edad media (RI), tiempo operatorio, estancia en el hospital, pérdida de sangre y número de ganglios linfáticos recuperados fueron 28 años (24-33), 135 minutos (120-180), 48 horas (24-48), 50 cc (20-100) y 14 (10-18) ganglios linfáticos, respectivamente. Todos los pacientes tenían marcador sérico negativo antes de la intervención. La presencia de metástasis en ganglios linfáticos se identificó en 32 (19,5%) pacientes. Se hizo un seguimiento en 15 de ellos. Catorce recibieron quimioterapia adyuvante y dos de ellos sufrieron recurrencia a los 3 y 64 meses. La ausencia de metástasis en ganglios linfáticos se diagnosticó en 132 (80,5%) pacientes. Se hizo un seguimiento en 80 de ellos. Entre ellos 7 sufrieron recurrencia (5 retroperitoneo, 2 pulmonar), uno de ellos a los 33 meses de la LRL. El seguimiento medio de los pacientes sin recurrencia fue de 14 meses (RI: 4-35). La tasa acumulada de supervivencia libre de enfermedad a los tres años fue del 82% (IC 95%: 64-91). Diecisiete de 164 (10%) padecieron complicaciones intra o perioperatorias.ଝ Este trabajo ha sido presentado parcialmente en la Reunión Anual de la Asociación Americana de Urología en Atlanta 2007.* Autor para correspondencia. Correo electrónico: octaviocastillo@vtr.net (O.A. Castillo).

show abstract

Quality of life after laparoscopic and open retroperitoneal lymph node dissection in clinical Stage I nonseminomatous germ cell tumor: A comparison study

Cited by 63 publications

References 18 publications

Laparoscopic Retroperitoneal Lymph Node Dissection for Low-Stage Testicular Cancer

Laparoscopic Retroperitoneal Lymph Node Dissection for Low-Stage Testicular Cancer

Clinical outcomes in patients with stage I non-seminomatous germ cell cancer

Linfadenectomía retroperitoneal laparoscópica primaria para el tumor testicular de células germinales no seminomatoso en estadio clínico I

Contact Info

Product

Resources

About